+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Comparative Effects of ACTH-Related Peptides on Acquisition of Shuttle-Box Avoidance Behavior of Hypophysectomized Rats

      , ,


      S. Karger AG

      ACTH-related peptides, Avoidance acquisition, Hypophysectomy

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Hypophysectomy resulted in a marked impaired acquisition of shuttle-box avoidance learning, when lower shock intensity (0.05 mA) was used as the unconditioned stimulus, but not when shock intensity was increased to 0.12 mA. Daily subcutaneous treatment with ACTH<sub>4-10</sub> (6 µg/day), ACTH<sub>4–7</sub> (6 µg/day), [Met(O2)<sup>4</sup>]ACTH<sub>4–7</sub> (2 µg/day), ACTH<sub>4-9 </sub>analog (Org 2766) (60 ng/day), and an ACTH<sub>4-10</sub> analog (HP 953 A) (60 ng/day) for 7 days normalized avoidance acquisition of hypophysectomized rats during the treatment period. The beneficial effect of the peptides was of a short-term nature, since it disappeared after discontinuation of the treatment. Microgram amounts of Org 2766 did not influence acquisition of hypophysectomized rats. [D-Phe<sup>7</sup>]ACTH<sub>4-10</sub> (60 µg/day) further reduced the already deficient acquisition of avoidance behavior of hypophysectomized rats. This latter effect may be due to an antagonistic effect towards brain-borne ACTH-related peptides. ACTH<sub>1-16</sub> -NH2 antiserum administered intracerebroventricularly 30 min prior to a massed-trial shuttle-box acquisition session reduced avoidance acquisition in hypophysectomized rats. This suggests that in addition to ACTH and related peptides from the pituitary, brain-borne ACTH-like peptides are involved in avoidance learning.

          Related collections

          Author and article information

          S. Karger AG
          26 March 2008
          : 36
          : 2
          : 112-118
          Rudolf Magnus Institute for Pharmacology, Medical Faculty, University of Utrecht, Utrecht, The Netherlands
          123446 Neuroendocrinology 1983;36:112–118
          © 1983 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article